INTRODUCTION

Euglena gracilis (Euglena) is a unicellular microalga that contains abundant nutrients, including vitamins and minerals, and has received much attention as a new ingredient of functional foods and feed (Aemiro et al., 2016; Matsumoto, Inui, Miyatake, Nakano, & Murakami, 2009). In addition, Euglena accumulates paramylon, a particulate \( \beta \)-1,3-glucan, as a carbon source. In a point of view of human health contributed by the \( \beta \)-1,3-glucan, it was reported that ingestion of barley or mushroom \( \beta \)-glucans altered gut microbiota and mitigate many diseases (Friedman, 2016; Wang et al., 2016). So, oral administration of Euglena or paramylon can be considered beneficial for human health. Indeed, oral administration of Euglena has been shown to ameliorate colon cancer (Watanabe, Shimada, Matsuyama, & Yuasa, 2015) and type 2 diabetes (Shimada et al., 2016) in rodents. Similarly, the administration of paramylon improved atopic dermatitis (Sugiyama et al., 2009) and mitigated carbon tetrachloride-induced liver injury (Sugiyama et al., 2009). Therefore, it is necessary to explore the functions of Euglena and paramylon further to obtain new insights into their potential as functional foods.

Non-alcoholic steatohepatitis (NASH), a metabolic syndrome, is the extreme form of non-alcoholic fatty liver disease (NAFLD) (Chalasani et al., 2012; Duvnjak et al., 2007). In most cases, NAFLD has few symptoms and is not accompanied by inflammation and fibrosis, whereas NASH may progress to cirrhosis and liver cancer without hepatitis virus infection or chronic alcohol intake. The incidence of NASH is increasing worldwide, and many clinical trials have indicated that several pharmacological agents, including angiotensin II receptor blockers (ARBs) or farnesoid X receptor (FXR) agonists, are effective in NASH treatment. In addition, functional foods are expected to be important alternatives for treating or preventing NASH. Recently, focus has been directed toward microalgae as dietary supplements, mainly for lifestyle-related diseases, because they contain various nutrients and functional ingredients. Specifically, a unicellular microalga Euglena gracilis stores a unique \( \beta \)-1,3-glucan particle called paramylon that stimulates the immune system. In this study, we evaluated the effects of Euglena and paramylon on NASH in Stelic Animal Model (STAM) mice using Sirius red staining and confirmed that oral administration of Euglena inhibits the process of liver fibrosis. Moreover, compared with controls, paramylon decreased non-alcoholic fatty liver disease (NAFLD) activity scores related to inflammation. These results indicate that the oral administration of Euglena and paramylon inhibits fibrosis and ameliorates NASH.

KEYWORDS

Euglena, fibrosis, microalgae, NASH, Paramylon
of NAFLD and NASH is rapidly increasing (Satapathy & Sanyal, 2015), and these diseases are expected to become a major global burden. Several studies have indicated that angiotensin II receptor blockers (ARBs) such as losartan and telmisartan or farnesoid X receptor (FXR) agonists may be effective in improving NASH symptoms (Arab, Karpen, Dawson, Arrese, & Trauner, 2016; Fujita et al., 2007; Hirata et al., 2013; Yoshiji et al., 2009); however, a definitive therapeutic option remains unavailable to date. Day et al. proposed a two-hit theory for NASH development (Day & James, 1998), but it remains to be confirmed. Specifically, fatty liver is first induced by excessive nutrition that exceeds the liver storage limit, which in turn causes oxidative damage to liver cells, resulting in NASH development.

Many NASH models, including genetic models and/or dietary models, have been established thus far (Hebbard & George, 2011). Although methionine-choline deficient (MCD) model is a typical diet-induced model of NASH, it shows an opposite metabolic profile to that of human NASH. In contrast, in Stelic Animal Model (STAM) mice (Fujii et al., 2013; Saito et al., 2015), fatty liver is triggered by streptozotocin-induced insulin resistance in combination with a high-fat diet and may be observed in 6-week-old animals. Subsequently, steatohepatitis, fibrosis, and hepatocellular carcinoma appear by 8, 9, and 20 weeks, respectively. This pathological development shares similar characteristics to that of human NASH, suggesting that this model can be applied for the investigation of the effect of functional foods or drug candidates. In this study, we report the anti-fibrotic effects of Euglena or paramylon in STAM mice.

2 | MATERIALS AND METHODS

2.1 | Test substance preparation

Euglena and paramylon were provided in powdered form by Euglena Co., Ltd. (Tokyo, Japan). The components of Euglena have been described previously (Shimada et al., 2016). Briefly, Euglena is composed of 29.4% carbohydrates, 42.3% protein, and 19.0% fat. Approximately 70–80% of carbohydrates in Euglena were assumed to be paramylon. Paramylon isolation was conducted using a standard method (Inui, Miyatake, Nakano, & Kitaoka, 1982).

2.2 | Animals and induction of NASH

Eighteen C57BL/6J SPF mice (14-day pregnant females) were obtained from Japan SLC (Shizuoka, Japan). Male pups delivered naturally were selected for NASH induction. NASH was induced as previously described. Two-day-old male mice were subcutaneously injected with 200 μg streptozotocin (20 μl/head) to confer insulin resistance. CE-2 (CLEA Japan, Japan) was fed freely until the weighing period (4-week-old). After that, the high-fat diet HFD32 (CLEA Japan, Japan) was fed to mice. Thirty-six STAM mice were divided into six groups (six mice/group, three mice/cage) to equalize the average body weight by stratified random sampling on the day before initiation of test substance administration (Figure 1).

2.3 | Administration of test substance

Saline solution was added to Euglena and paramylon dried powder just before administration.

In a single treatment, Euglena, paramylon (each 3.0 g/kg), and telmisartan (10 mg/kg) were orally administered with a feeding needle (10 ml/kg). Vehicle was also administered (10 ml/kg). Each treatment quantity (minimum adjustable quantity: 0.01 ml) was determined based on body weight on the day of treatment. Daily administration (once a day) started at 5 weeks of age and continued for 27 days.

2.4 | Sirius red staining

Liver fibrosis was assessed with Sirius red staining. Sections from paraffin blocks were stained with 0.03% Sirius red solution (Waldeck, Germany) after hydrophilization. The stained sections were dehydrated for observation. The obtained pictures were analyzed using ImageJ software (National Institutes of Health).

2.5 | Hematoxylin and eosin staining and NAFLD activity score calculation

Hematoxylin and eosin (HE) staining was performed as described previously (Fuji et al., 2013). NAFLD activity scores (NAS) were calculated based on the criteria of Kleiner et al. (Kleiner et al., 2005) (see also Table 1).

2.6 | Immunohistochemistry of livers

For immunohistochemistry, sections were cut from frozen liver tissues embedded in Tissue-Tek O.C.T. compound and fixed in acetone. Endogenous peroxidase activity was blocked with 0.03% H2O2 for 5 min, followed by incubation with Block Ace (Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan) for 10 min. The sections were incubated with a 100-fold dilution of anti-F4/80 antibody (BMA Biomedicals, Augst, Switzerland) at 4°C overnight. The sections were then incubated with biotin-conjugated secondary antibody (VECTASTAIN Elite ABC kit, Vector Laboratories, Burlingame, CA, USA), followed by ABC reagent each for 30 min at 23–25°C. Enzyme-substrate reactions were performed using 3, 3′-diaminobenzidine/H2O2 solution (Nichirei Bioscience Inc., Tokyo, Japan). The sections were incubated with a 200-fold dilution of anti-α-SMA antibody (rabbit monoclonal antibody, ab32575; Abcam, Cambridge, UK) at 4°C overnight.
After incubation with secondary antibody (HRP-goat anti-rabbit antibody, Vector Laboratories, Inc.), enzyme-substrate reactions were performed using 3, 3′-diaminobenzidine/H$_2$O$_2$ solution (Nichirei Bioscience Inc.).

For quantitative analyses of inflammation and α-SMA-positive areas, bright field images of F4/80- and α-SMA-immunostained sections were captured around the central vein using a digital camera (DFC295; Leica, Wetzlar, Germany) at 200-fold magnification. The positive areas in five fields/section were measured using ImageJ software (National Institute of Health, Bethesda, MD, USA).

### 2.7 RNA extraction and analysis of gene expression of liver injury and fibrogenic markers

Total RNA was extracted from STAM mice liver by using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer’s instructions. cDNA was synthesized from 50 ng of total RNA by using Rever Tra Ace qPCR RT Master Mix (Toyobo, Osaka, Japan). Real-time quantitative polymerase chain reaction (RT-qPCR) was performed in StepOne plus system (Thermo Fisher Scientific) using the PowerUP SYBR green Master mix (Applied Biosystems Inc., Warrington, UK). Target gene-specific primers are listed in Table 2. The level of target gene expression was determined by comparing with a reference gene (GAPDH) based on $2^{-\Delta\Delta C_{t}}$ method (Livak & Schmittgen, 2001).

### 2.8 Statistical analysis

Statistical analysis was performed using Bonferroni multiple comparison test or Student’s t test using Prism 6 software (GraphPad Software, La Jolla, CA, USA). Comparisons were made between the following groups: (a) vehicle-Euglena, (b) vehicle-paramylon, and (c) vehicle-telmisartan. The average of each group was expressed as means ± SD. p values < 0.05 were considered statistically significant. A trend or tendency was assumed when a Student’s t test returned p values < 0.05.

### 3 RESULTS

#### 3.1 General findings

To assess whether experimental design was appropriate or not, blood glucose levels were measured after Euglena, paramylon, and telmisartan treatment on STAM mice. As the results, the blood glucose level after Euglena and paramylon treatment was approximately same with the vehicle as control (average of blood glucose levels in each test group: vehicle; 670, Euglena; 640, and paramylon; 570 mg/dl). Furthermore, in case of telmisartan treatment, the average of blood glucose levels was 1070 mg/dl (Table 3). These results supported that the experimental design was appropriate, because the blood glucose level in each test group was same or higher than vehicle. The average body and liver weights of each group were subsequently measured. Telmisartan-treated mice showed a significantly greater decrease in body weight than the vehicle group mice from days 24 to 27 (Figure 2a). A significant decrease of liver weight was also confirmed in addition to a decrease in body weight and liver-body weight ratio (Figure 2b–d), suggesting that lipid accumulation...
was suppressed by telmisartan. In contrast, no significant changes were observed in Euglena, paramylon, and vehicle groups. Plasma alanine transaminase (ALT) and liver triglyceride levels are general biomarkers of liver condition and are suitable for monitoring NASH progression. Compared with the vehicle group, the telmisartan-treated group showed a decrease in the levels of plasma ALT and liver triglycerides (Figure 2e,f). However, no differences were observed between the other groups.

3.2 | Sirius red staining area

To evaluate liver damage due to NASH progression as indicated by collagen aggregation, Sirius red-stained images were observed. In the vehicle group, positive staining reflecting collagen aggregation was clearly observed around the interlobular portal vein, sinusoid wall, and central vein wall (Figure 3a). Telmisartan, Euglena, and paramylon groups presented a significant decrease in positively stained area (average of positively stained area in each test group: vehicle; 1.11, Euglena; 0.76, and paramylon; 0.74, telmisartan; 0.70%) (Figure 3b). These results indicated that Euglena and paramylon treatment could contribute potentially to attenuate NASH progression on STAM mice.

3.3 | NAFLD activity scores

To confirm the attenuation effect of Euglena and paramylon on NASH progression, a histological assay was conducted against liver sections of each group by HE staining (see Materials and Methods section). As expected from the results of Sirius red staining assay (Figure 3), steatosis, lobular inflammation, and hepatocyte ballooning were observed in all groups (Figure 4a). Based on the criteria given in Table 1, NAS were calculated and compared between the groups. NAS of the telmisartan group were significantly lower than that of the vehicle group. Moreover, the paramylon group showed a decreasing trend of NAS (Figure 4b), although no change was observed in the Euglena group (average of NAS in each test group: vehicle; 4.5, Euglena; 4.0, and paramylon; 3.3, telmisartan; 2.7). Specifically, ballooning and inflammation scores, but not steatosis, contributed to the improvement of total score of the paramylon group (Figure 4c–e).

3.4 | Immunostaining of liver

To elucidate the mechanism underlying the anti-NASH and anti-fibrotic effects, immunostaining of F4/80, α-SMA, and calculation of positive area ratio were performed using a liver sample.

### Table 3: Plasma blood glucose

|                | Vehicle | Euglena | Paramylon | Telmisartan |
|----------------|---------|---------|-----------|-------------|
| Ave            | 668     | 644     | 567       | 1,072       |
| SD             | ±103.6  | ±56.4   | ±61.6     | ±109.4      |

**FIGURE 2** General findings in STAM mice administered test substances. Comparison of (a) body weight change, (b) body weight, (c) liver weight, (d) liver-to-body weight ratio, (e) plasma ALT, and (f) liver triglycerides in each group. Vehicle (black), Euglena (red), paramylon (green), telmisartan (gray). Asterisks indicate statistical significances ($p < 0.01$ or $p < 0.05$), while n.s. indicates “not significant.”
First, F4/80 reflecting the degree of inflammation was shown. In the telmisartan group, the positive area ratio due to F4/80 liver immunostaining was significantly decreased, while the Euglena and paramylon groups showed a decreasing trend in the positive area ratio due to F4/80 liver immunostaining (average of F4/80-positive area in each test group: vehicle; 2.57, Euglena; 1.56, paramylon; 1.46, telmisartan; 0.92%) (Figure 5a). Although no significant difference was observed, both Euglena and paramylon groups showed decreased positive area ratio of F4/80 by approximately 40% compared by vehicle. In contrast, α-SMA reflecting the activation degree of hepatic stellate cells was shown. In the telmisartan, Euglena, and paramylon groups, the
positive area rate due to immunostaining of α-SMA liver showed a decreasing trend (average of α-SMA-positive area in each test group: vehicle; 2.19, Euglena; 1.32, and paramylon; 1.47, telmisartan; 1.10%) (Figure 5b). Although no significant difference was observed, both Euglena and paramylon groups showed decreased positive area ratio of α-SMA by approximately 40% compared by vehicle.

3.5 Gene expression of liver injury and fibrogenic markers

Regarding inflammation-related genes (IL-1β, IL-6, TNF-α, and MCP-1) in the Euglena and paramylon groups, the expression of each gene tended to increase compared with the control group. Regarding inflammation-related genes in the telmisartan group, there was no increase in the expression level of each gene compared with the control group (Figure 6a).

In contrast, α-SMA gene expression tended to decrease in telmisartan and paramylon groups (Figure 6b). Moreover, there was no clear difference in expression level of collagen gene (Col1a2, Col3a1; Figure 6c).

4 DISCUSSION

In this study, we evaluated the effect of Euglena and paramylon using STAM mice as an NASH model. Only the telmisartan group showed body and liver weight loss after 27 days, indicating the effectiveness of telmisartan as a pharmaceutical drug (Figure 1). Conversely, Euglena- and paramylon-treated groups presented amelioration of liver fibrosis; however, these groups did not show body and liver weight loss. Furthermore, the paramylon group showed a trend toward improved NAFLD score.

The progression of fibrosis is mainly attributed to inflammation and/or abnormal collagen accumulation (Caldwell & Argo, 2010; Friedman, 2010). The Sirius red positively stained area decreased in both Euglena- and paramylon-treated groups, suggesting that collagen overproduction was suppressed by both test substances. In the paramylon group, NAFLD scores, especially inflammation scores, tended to decrease, suggesting that paramylon delayed fibrosis via inflammation inhibition. Regarding inflammation-related genes, the expression levels in Euglena- and paramylon-treated groups increased relative to the control group (Figure 6a). F4/80 immunostaining showed a trend toward decrease in positive area ratio (Figure 5a). Thus, gene expression and immunostaining showed opposite trends.
It is suggested that this mismatch is caused by the time lag between gene and protein expression. Reduction in F4/80-positive area ratio by these test substances is presumed to be due to the inhibition of swelling of positive cells and suppression of infiltration around positive vein. These test substances are activated by activation of liver macrophages/Kupffer cells. There is a possibility that macrophages/Kupffer cells may suppress the effect on migration.

Oxidative stress is linked to hepatocyte ballooning development, suggesting that radical scavengers act against NASH progression, as explained by the two-hit theory (Day & James, 1998). Given that paramylon intake contributes to hepatoprotection through its antioxidant activity (Sugiyama et al., 2009), it is possible that this compound is also effective as a radical scavenger. Indeed, ballooning scores tended to improve in the paramylon group (Figure 4e). However, NAFLD scores did not improve in Euglena-treated animals, suggesting that Euglena is not involved in the inhibition of inflammation, but may be effective in activating hepatic stellate cells, resulting in attenuation of collagen overproduction. A decrease in α-SMA gene expression in the paramylon group and a decrease in α-SMA-positive area ratio of immunostaining in the Euglena and paramylon groups were observed, suggesting suppression of hepatic stellate cell activation (Figures 5b and 6b).

Since there was no clear difference in the expression level of collagen gene (Figure 6c), it was considered that Euglena andParamylon may be involved in collagen metabolism and not collagen synthesis. In a previous epidemiological study, a strong association between diabetes and NAFLD was reported (Ortiz-Lopez et al., 2012). It is known that Euglena inhibits hyperglycemia and bulimia in OLETF rats (Shimada et al., 2016), suggesting that this microalga may also affect insulin resistance and suppress fibrosis in STAM mice.

Blood directly reaches the liver via the portal vein from the gut, indicating that the liver is sensitive to the gut environment. It is already known that alteration of gut microbiota, as well as endotoxins produced by them, is related to NASH progression (Bashiardes, Shapiro, Rozin, Shibolet, & Elinav, 2016). The oral administration of Euglena provides multiple nutrients to the gut microorganisms of STAM mice. Therefore, we speculate that Euglena intake alters gut microbiota composition, which may lead to an anti-fibrotic effect. Beta-1,3-glucan paramylon intake may also alter gut microbiota composition. However, utilization of paramylon as a carbon source for most microbiota seems to be difficult. Previously observed amelioration of autoimmune diseases, including atopic dermatitis (Sugiyama et al., 2010), supports that immune modulation is induced through gut microbiota alteration by Euglena or paramylon intake.

In this study, we used Euglena powder containing 20% paramylon. Hence, the Euglena group was administered paramylon as well. However, the anti-inflammatory effect observed in the paramylon group was not observed in the Euglena group, indicating that the dosage of paramylon administered in the Euglena group was not sufficient for it to be effective. These results suggest that Euglena and paramylon inhibit fibrosis via different mechanisms. Hepatitis, fibrosis, and hepatocellular carcinoma are sequentially caused in fatty liver, resulting in liver failure. Therefore, it is inferred that the inhibition of fibrosis is the key in preventing carcinoma. Euglena and paramylon did not have as dramatic an effect as telmisartan did in

![FIGURE 6](image-url) Gene expression of liver injury and fibrogenic markers (a) inflammation-related genes (IL-1β, IL-6, TNF-α, and MCP-1) (b) α-SMA gene expression. (c) collagen gene expression (Col1a2, Col3a1). Vehicle (black), Euglena (red), paramylon (green), telmisartan (gray). n.s. indicates "not significant"
the treatment of NASH. However, sustained intake of Euglena and paramyln as supplements may be effective for the prevention of NASH progression.

ACKNOWLEDGMENTS

The authors greatly appreciate the useful suggestions and technical support from SMC laboratories.

ETHICAL STATEMENTS

This study was supported by euglena Co., Ltd. AN, OL, and KS are working in R&D department of euglena Co., Ltd. All animals were housed and cared for in accordance with the Japanese pharmacological Society Guidelines for Animal Use. All raw data are disclosed in Supporting Information Table S1.

ORCID

Ayaka Nakashima http://orcid.org/0000-0001-7474-406X

REFERENCES

Aemiro, A., Watanabe, S., Suzuki, K., Hanada, M., Umetsu, K., & Nishida, T. (2016). Effects of Euglena (Euglena Gracilis) supplemented to diet (Forage: Concentrate ratios of 60:40) on the Basic Rumin Fermentation and Methane Emissions in in Vitro Condition. Animal Feed Science and Technology, 212, 129–135. https://doi.org/10.1016/j.anifeedsci.2015.12.010

Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M., & Trauner, M. (2016). Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology, 65, 350–362. http://www.ncbi.nlm.nih.gov/pubmed/27358174.

Bashirades, S., Shapiro, H., Rozin, S., Shibolet, O., & Elinav, E. (2016). Non-alcoholic fatty liver and the gut microbiota. Molecular Metabolism, 5(9), 782–794. https://doi.org/10.1016/j.molmet.2016.06.003

Caldwell, S., & Argo, C. (2010). The natural history of non-alcoholic fatty liver disease. Digestive Diseases, 28(1), 162–168.

Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., ... American College of Gastroenterology (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american association for the study of liver diseases, american college of gastroenterology, and the American gastroenterological association. Hepatology, 55(6), 2005–2023.

Day, C. P., & James, O. F. (1998). Steatohepatitis: A tale of two hits? Gastroenterology, 114(4), 842–845. http://www.ncbi.nlm.nih.gov/pubmed/9547102.

Duvnjak, M., Lerotić, I., Barić, N., Tomasić, V., Virović Žukić, L., & Velagić, V. (2007). Pathogenesis and management issues for non-alcoholic fatty liver disease. World journal of gastroenterology, 13(34), 4539–4550. http://www.ncbi.nlm.nih.gov/pubmed/17729403%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4611824.

Friedman, S. L. (2010). Mechanisms of hepatic fibrogenesis. Gastroenterology, 134(6), 1655–1669.

Friedman, M. (2016). Mushroom polysaccharides: Chemistry and cantiobesity, antidiabetes, antiacancer, and antibiotic properties in cells, rodents, and humans. Foods, 5(4), 50. http://www.mdpi.com/2304-8158/5/4/80.

Fujii, M., Shibazaki, Y., Wakamatsu, K., Honda, Y., Kawauchi, Y., Suzuki, K., ... Yoneyama, H. (2013). A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Medical Molecular Morphology, 46(3), 141–152.

Fujita, K., Yoneda, M., Wada, K., Mawatari, H., Takahashi, H., Kikuchi, H., ... Nakajima, A. (2007). Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Digestive Diseases and Sciences, 52(12), 3455–3464.

Hirata, T., Tomita, K., Kawai, T., Yokoyama, H., Shimada, A., Kikuchi, M., ... Hibi, T. (2013). Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease: Fatty liver protection trial by telmisartan or losartan study (FANTASY). International Journal of Endocrinology, 2013, 587140.

Inui, H., Miyatake, K., Nakano, Y., & Kitaoka, S. (1982). Wax ester fermentation in euglena gracilis. FEBS Letters, 150(1), 89–93.

Kleiner, D. E., Brunt, E. M., Van Natta, M., Bending, C., Contos, M. J., Cummings, O. W., ... Nonalcoholic Steatohepatitis Clinical Research Network (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 41(6), 1313–21.

Livak, K. J., & Schmittgen, T. D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and 2-DDCT method. Methods, 25(4), 402–408.

Mandrekar, P., Ambade, A., Lim, A., Szabo, G., & Catalano, D. (2011). An essential role for MCP-1 alcoholic liver injury: Regulation of proinflammatory cytokines and hepatic steatosis. Hepatology, 54(6), 2185–2197.

Matsumoto, T., Inui, H., Miyatake, K., Nakano, Y., & Murakami, K. (2009). Comparison of nutrients in euglena with those in other representative food sources. Eco-Engineering, 21(2), 81–86.

Oben, J. A., Mouralidarane, A., Samuelsson, A.-M., Matthews, P. J., Morgan, M. L., Mckee, C., ... Taylor, P. D. (2010). Maternal obesity during pregnancy and lactation programs the development of offspring non-alcoholic fatty liver disease in mice. Journal of Hepatology, 52(6), 913–920.

Ortiz-Lopez, C., Lomonaco, R., Orsak, B., Finch, J., Chang, Z., Kochunov, V. G., ... Cusi, K. (2012). Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care, 35(4), 873–877.

Saito, K., Uebano, T., Maekawa, K., Ishikawa, M., Taguchi, R., Nammo, T., ... Saito, Y. (2015). Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis. Scientific reports, 5(1), 12466. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4542160&tool=pmcentrez&rendertype=abstract.

Satapathy, S. K., & Sanyal, A. J. (2015). Epidemiology and natural history of nonalcoholic fatty liver disease. Seminars in Liver Disease, 35, 221–235.

Shimada, R., Fujita, M., Yuasa, M., Sawamura, H., Watanabe, T., Nakashima, A., & Suzuki, K. (2016). Oral administration of green algae, euglena gracilis, inhibits hyperglycemia in OLETF rats, a model of spontaneous type 2 diabetes. Journal of Veterinary medical science the Japanese Society of Veterinary Science, 72(6), 755–763.

Sugiyama, A., Hata, S., Suzuki, K., Yoshida, E., Nakano, R., Mitra, S., ... Takeuchi, T. (2010). Oral administration of paramylon, a beta-1,3-D-glucan isolated from Euglena Gracilis Z inhibits development of atopic dermatitis-like skin lesions in NC/Nga mice. The Journal of Veterinary medical science/the Japanese Society of Veterinary Science, 72(6), 755–763.
Wang, Y., Ames, N. P., Tun, H. M., Tosh, S. M., Jones, P. J., & Khafipour, E. (2016). High molecular weight barley β-glucan alters gut microbiota toward reduced cardiovascular disease risk. *Frontiers in Microbiology*, 7, 1-15.

Watanabe, T., Shimada, R., Matsuyama, A., & Yuasa, M. (2015). *Food & function* antitumor activity of the B-glucan paramylon from *Euglena* against preneoplastic colonic aberrant crypt.

Yoshiji, H., Noguchi, R., Ikenaka, Y., Namisaki, T., Kitade, M., Kaji, K., ... Fukui, H. (2009). Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. *BMC research notes*, 2, 70. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2686718&tool=pmcentrez&rendertype=abstract.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Nakashima A, Sugimoto R, Suzuki K, et al. Anti-fibrotic activity of *Euglena gracilis* and paramylon in a mouse model of non-alcoholic steatohepatitis. *Food Sci Nutr*. 2019;7:139–147. https://doi.org/10.1002/fsn3.828